EUFLEXXA STUDY RESULTS REPORTED

A head-to-head study has demonstrated the efficacy and greater tolerability of Euflexxa (highly purified hyaluronan) compared to Synvisc, an avian-derived hyaluronan and the leading hyaluronic acid (HA) product in its class for the treatment of osteoarthritis (OA) knee pain.

In the 12-week trial of 321 patients, Euflexxa showed statistically significant advantages over Synvisc. More patients treated with Euflexxa were symptom-free, there was a lower incidence of joint effusion, fewer patients required supplemental simple analgesics, and more patients reported being "very satisfied." The study was published in the journal Osteoarthritis and Cartilage.